What Is Drug Design?

Drug design is the process of identifying and optimising chemical compounds that interact with a biological target in a way that produces a desired therapeutic effect. The field combines medicinal chemistry, structural biology, pharmacology, and computational science to move from knowledge of a disease mechanism and its molecular actors to a candidate molecule suitable for clinical evaluation. Modern drug design is overwhelmingly iterative: an initial compound identified through screening or modelling is refined through many rounds of synthesis and biological testing to improve its potency, selectivity, metabolic stability, and safety profile.

The discipline distinguishes between two broad approaches. Structure-based drug design (SBDD) uses experimentally determined or computationally predicted three-dimensional structures of the biological target, typically a protein, to guide the design of molecules that fit and bind to its active or allosteric site. Ligand-based drug design (LBDD) derives design rules from the pharmacological profiles of known active compounds when target structure information is unavailable, using quantitative structure-activity relationships (QSAR) and pharmacophore modelling to predict which structural modifications will improve activity.

Structure-Based Methods

Structure-based drug design relies on atomic-resolution structures obtained from X-ray crystallography, cryo-electron microscopy, or computational homology modelling to reveal the geometry and chemical character of a target binding site. Molecular docking algorithms place candidate ligands into the site and score the predicted binding pose using empirical or physics-based energy functions that estimate steric complementarity, hydrogen bonding, and electrostatic interactions. Virtual screening applies docking to large compound libraries, often containing millions of commercially available molecules, to identify candidates worth synthesising and testing. Fragment-based drug design (FBDD) starts from small, weakly binding fragments that can be detected crystallographically and grows or links them into potent lead compounds with better physicochemical properties. The historical development and current capabilities of computer-aided drug design are reviewed in IEEE Xplore coverage of computational drug discovery and molecular simulation for medicinal chemistry.

Ligand-Based Methods and QSAR

When target structure is unknown or the binding mode is difficult to model, QSAR methods derive mathematical relationships between molecular descriptors and measured biological activity across a training set of compounds. Descriptors capture molecular features such as lipophilicity (logP), molecular weight, hydrogen-bond donor and acceptor counts, topological polar surface area, and shape indices. A QSAR model predicts the activity of new compounds from their descriptors, enabling rapid prioritisation without synthesis. Pharmacophore models abstract the essential spatial arrangement of chemical features required for activity and can be used to search three-dimensional compound databases for scaffolds that present those features in the correct geometry. The PMC review of computational approaches in drug screening and design surveys both QSAR and pharmacophore approaches along with their validation requirements and applicability domain considerations.

Artificial Intelligence in Drug Design

Machine learning and deep learning have substantially changed drug design practice since the early 2020s. Graph neural networks represent molecules as graphs of atoms and bonds, learning representations that capture chemical context far more expressively than hand-crafted descriptors. Generative models including variational autoencoders and diffusion models can propose novel molecular structures optimised for multiple properties simultaneously, operating in latent chemical spaces too large to enumerate explicitly. AlphaFold2 and its successors have made high-confidence protein structure prediction accessible for essentially any protein of known sequence, expanding the fraction of the proteome amenable to structure-based design. A survey of how these methods accelerate discovery pipelines is provided in Nature's paper on computational approaches streamlining drug discovery.

Applications

Drug design has applications in a wide range of fields, including:

• Oncology, for designing kinase inhibitors and targeted therapies that selectively act on tumour-specific mutations
• Infectious disease, for antiviral and antibacterial agents developed against pathogen proteins identified through structural genomics
• Neurology, for compounds targeting GPCRs and ion channels implicated in Alzheimer's disease, Parkinson's disease, and depression
• Rare and neglected diseases, where computational approaches reduce the cost barrier to lead identification
• Agrochemicals, applying the same structure-based and QSAR methods to design pesticides and herbicides with improved environmental safety profiles